Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | HPN | P05981 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494033 | 0.89 | ALOX15 (0.46) | ALOX15CKS1BSKP1SKP2BCHE | |
| SCHEMBL6495090 | 0.85 | MEN1 (0.38) | ALOX15CCNT1CDK9HPNBCHE | |
| SCHEMBL6933336 | 0.81 | ALOX15 (0.43) | ALOX15NPSR1 | |
| SCHEMBL6495272 | 0.80 | ALOX15 (0.34) | ALOX15KCNQ2KDR | |
| SCHEMBL6504814 | 0.75 | ACLY (0.38) | ALOX15NPSR1 | |
| SCHEMBL6494231 | 0.75 | ALOX15 (0.36) | ALOX15 | |
| SCHEMBL6501121 | 0.75 | LTB4R (0.37) | ALOX15NPSR1 | |
| SCHEMBL6497603 | 0.74 | LTB4R (0.37) | ALOX15NPSR1 | |
| SCHEMBL6494027 | 0.73 | ALOX15 (0.48) | ALOX15BCHENPSR1 | |
| SCHEMBL6503850 | 0.73 | ACLY (0.38) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | claimed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | claimed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | ALOX15 1/4885CCNT1 1366/4885CDK9 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.